Bookmarks (6) clear filters

Summary List Placement Remdesivir was the first coronavirus treatment to be approved by the US Food and Drug Administration. Originally developed by pharma giant Gilead Sciences to treat Ebola, the drug got emergency authorization from the FDA in May. A study published the same month found that it shortened recovery times for seriously ill COVID-19 patients. Last month, remdesivir earned full FDA approval.  But...

Summary List Placement The 1918 flu pandemic sparked three waves of infections, the deadliest of which occurred in the fall. The US is now on track to see a similar trend, experts say. The nation's new daily cases have risen nearly 40%, on average, since October 1.  Experts predict this third surge could be the deadliest yet due to a perfect storm of factors....

Summary List PlacementWhite House physician Sean Conley admitted at a Sunday briefing that President Trump was given supplemental oxygen on Saturday, which he declined to acknowledge at yesterday's briefing. "I was trying to reflect the upbeat attitude that the team, the president, over his course of illness, has had," he said. "I didn't want to give any information that might steer the course of...

Summary List Placement Last weekend, President Donald Trump was still beaming from a White House event where he formally announced Amy Coney Barrett as his latest nominee to the Supreme Court. But by the following day, his week started to take very unexpected turns.  On Sunday, the president's financial records were released in a blockbuster report by The New York Times, revealing Trump had...

President Donald Trump is prepared to deliver news of a "major therapeutic breakthrough" for the novel coronavirus on Sunday, White House Press Secretary Kayleigh McEnany said in a tweet late Saturday. The president yesterday took aim at the Food and Drug Administration, claiming that the agency was part of a conspiracy to slow down vaccine trials until after the November election. McEnany said FDA...

Gilead Sciences could be justified in charging up to $4,500 per coronavirus patient for its drug, a nonprofit pricing watchdog said in a recent report.  The California biotech is the maker of remdesivir, an experimental antiviral treatment that helped hospitalized COVID-19 patients recover 31% faster, shaving four days off hospital stays.  The company has yet to give a pricing strategy for remdesivir, beyond pledging...